| |
|
OMT’s antibody platform has freedom to operate and broad patent protection.
OMT has developed a new genetic engineering approach using transgenic rats. The
technology will provide potential partners freedom to operate.
The genetic engineering of mice and rabbits (including artificial immunoglobulin loci, inactivation of endogenous antibody production, and
generation of human antibodies) and the use of antibodies from these animals are subject to a large number of issued patents and filed patent
applications. These patent estates limit the freedom of new antibody platforms based on genetically engineered animals.
OMT has filed a patent application covering its platform technology, including OMT's animals, its methods, the transgenes used to make the animals,
and the antibodies and novel immunoglobulin compositions from the animals. The company also has a worldwide non-exclusive license from Sangamo BioSciences, Inc. for the use of ZFNs. OMT has exclusive commercial rights for the ZFN-mediated inactivation of rat immunoglobulin genes.
|
|
|
|
